JPMorgan Chase & Co. Has $657.60 Million Holdings in Astrazeneca Plc $AZN

JPMorgan Chase & Co. cut its stake in shares of Astrazeneca Plc (NYSE:AZN) by 22.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,746,985 shares of the company’s stock after selling 1,077,087 shares during the period. JPMorgan Chase & Co. owned about 0.24% of Astrazeneca worth $657,596,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Triumph Capital Management acquired a new position in shares of Astrazeneca during the third quarter worth $25,000. Bangor Savings Bank increased its holdings in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after buying an additional 154 shares in the last quarter. Eagle Bay Advisors LLC acquired a new position in shares of Astrazeneca during the fourth quarter worth $30,000. YANKCOM Partnership acquired a new position in shares of Astrazeneca during the fourth quarter worth $31,000. Finally, TFC Financial Management Inc. increased its holdings in shares of Astrazeneca by 3,350.0% during the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after buying an additional 335 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Stock Performance

Shares of Astrazeneca stock opened at $183.36 on Wednesday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a market cap of $284.38 billion, a price-to-earnings ratio of 27.53, a P/E/G ratio of 1.56 and a beta of 0.25. The company’s fifty day moving average is $190.49 and its 200 day moving average is $185.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Sell-side analysts forecast that Astrazeneca Plc will post 9.53 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on AZN. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings started coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.